https://actuatetherapeutics.com/ 2026-11-10T16:03:20+00:00 https://actuatetherapeutics.com/publications/glycogen-synthase-kinase-3-a-new-therapeutic-target-in-renalcell-carcinoma/ 2022-05-19T11:10:09+00:00 https://actuatetherapeutics.com/publications/gsk-3β-inhibitor-9-ing-41-reduces-cell-viability-and-halts-proliferation-of-b-cell-lymphoma-cell-lines-as-a-single-agent-and-in-combination-with-novel-agents/ 2022-05-19T11:16:12+00:00 https://actuatetherapeutics.com/publications/deregulated-gsk3β-activity-in-colorectal-cancer-its-association-with-tumor-cell-survival-and-proliferation/ 2022-05-19T11:22:27+00:00 https://actuatetherapeutics.com/publications/inactivation-of-glycogen-synthase-kinase-3-a-downstream-target-of-the-raf-1-pathway-is-associated-with-growth-suppression-in-medullary-thyroid-cancer-cells/ 2022-05-19T11:24:58+00:00 https://actuatetherapeutics.com/publications/glycogen-synthase-kinase-3β-ablation-limits-pancreatitis-induced-acinar-to-ductal-metaplasia/ 2024-09-03T09:25:05+00:00 https://actuatetherapeutics.com/publications/gsk-3-inhibition-overcomes-chemoresistance-in-human-breast-cancer/ 2024-09-03T09:32:18+00:00 https://actuatetherapeutics.com/publications/glycogen-synthase-kinase-3-in-mll-leukaemia-maintenance-and-targeted-therapy/ 2024-09-03T09:47:30+00:00 https://actuatetherapeutics.com/publications/glycogen-synthase-kinase-3β-inhibitors-induce-apoptosis-in-ovarian-cancer-cells-and-inhibit-in-vivo-tumor-growth/ 2024-09-03T09:51:03+00:00 https://actuatetherapeutics.com/presentations/exploring-mechanisms-of-resistance-to-elraglusib-in-pancreatic-cancer-pdx-models/ 2024-09-04T08:52:14+00:00 https://actuatetherapeutics.com/publications/targeting-gsk-3-a-promising-approach-for-cancer-therapy/ 2024-09-04T09:26:57+00:00 https://actuatetherapeutics.com/publications/9-ing-41-a-small-molecule-inhibitor-of-gsk-3beta-potentiates-the-efects-of-anticancer-therapeutics-in-bladder-cancer/ 2024-09-04T09:41:20+00:00 https://actuatetherapeutics.com/publications/gsk-3-inhibitor-elraglusib-9-ing-41-to-enhance-tumor-infiltrating-immune-cell-activation-in-tumor-biopsies-and-synergize-with-anti-pd-l1-in-a-murine-model-of-colorectal-cancer/ 2024-09-04T09:44:55+00:00 https://actuatetherapeutics.com/presentations/in-silico-approaches-to-patient-selection-credentialing-elraglusib-as-a-novel-treatment-in-metastatic-melanoma-resistant-to-checkpoint-inhibitors/ 2024-09-04T09:54:26+00:00 https://actuatetherapeutics.com/publications/plasma-cytokine-profiles-and-survival-outcomes-in-the-1801-phase-1-2-clinical-trial-of-9-ing-41-elraglusib-in-patients-with-advanced-cancer/ 2024-09-04T09:55:33+00:00 https://actuatetherapeutics.com/presentations/multimodal-mechanism-of-action-of-the-gsk-3-inhibitor-9-ing-41-elraglusib-includes-an-immunomodulatory-component-preliminary-results-from-the-1801-phase-1-2-trial/ 2024-09-04T09:57:09+00:00 https://actuatetherapeutics.com/publications/phase-1-2-study-of-elraglusib-9-ing-41-a-small-molecule-selective-glycogen-synthase-kinase-3-beta-gsk-3β-inhibitor-alone-or-with-irinotecan-temozolomide-irinotecan-or-cyclophosphamide-top/ 2024-09-04T10:01:11+00:00 https://actuatetherapeutics.com/presentations/targeting-gsk-3-a-new-approach-for-the-treatment-of-neuroblastoma/ 2024-09-04T10:29:46+00:00 https://actuatetherapeutics.com/presentations/the-glycogen-synthase-kinase-3-inhibitor-9-ing-41-synergize-with-chemotherapy-to-inhibit-pancreatic-tumor-growth-in-vivo/ 2024-09-04T10:34:28+00:00 https://actuatetherapeutics.com/presentations/aberrant-nuclear-expression-of-gsk-3β-in-human-head-and-neck-carcinoma/ 2024-09-04T10:56:14+00:00 https://actuatetherapeutics.com/presentations/corporate-presentation-stifel-2023-targeted-oncology-days/ 2024-09-04T10:57:05+00:00 https://actuatetherapeutics.com/publications/targeting-glycogen-synthase-kinase-3-for-therapeutic-benefit-in-lymphoma/ 2024-09-04T11:35:31+00:00 https://actuatetherapeutics.com/publications/tumor-microenvironment-modulating-oncolytic-adenovirus-combined-with-gsk-3β-inhibitor-enhances-antitumor-immune-response-against-bladder-cancer/ 2024-09-05T08:22:56+00:00 https://actuatetherapeutics.com/publications/gsk-3-inhibitor-elraglusib-enhances-tumor-infiltrating-immune-cell-activation-in-tumor-biopsies-and-synergizes-with-anti-pd-l1-in-a-murine-model-of-colorectal-cancer/ 2024-09-05T08:26:13+00:00 https://actuatetherapeutics.com/publications/9-ing-41-a-small-molecule-inhibitor-of-gsk-3β-potentiates-the-effects-of-chemotherapy-on-colorectal-cancer-cells/ 2024-09-05T08:28:39+00:00 https://actuatetherapeutics.com/publications/malignant-glioma-subset-from-actuate-1801-phase-i-ii-study-of-9-ing-41-gsk-3β-inhibitor-monotherapy-or-combined-with-chemotherapy-for-refractory-malignancies/ 2024-09-05T08:31:08+00:00 https://actuatetherapeutics.com/publications/the-tumor-suppressor-protein-traf3-modulates-gsk3-activity-and-susceptibility-of-b-lymphoma-cells-to-gsk3-inhibition/ 2024-09-05T08:34:53+00:00 https://actuatetherapeutics.com/publications/clinical-activity-of-9-ing-41-a-small-molecule-selective-glycogen-synthase-kinase-3-beta-gsk-3β-inhibitor-in-refractory-adult-t-cell-leukemia-lymphoma/ 2024-09-05T08:38:28+00:00 https://actuatetherapeutics.com/publications/pharmaceutical-inhibition-of-glycogen-synthetase-kinase-3β-reduces-multiple-myeloma-induced-bone-disease-in-a-novel-murine-plasmacytoma-xenograft-model/ 2024-09-05T08:40:23+00:00 https://actuatetherapeutics.com/publications/tumor-growth-suppression-using-a-combination-of-taxol-based-therapy-and-gsk3-inhibition-in-non-small-cell-lung-cancer/ 2024-09-05T08:46:23+00:00 https://actuatetherapeutics.com/publications/elraglusib-9-ing-41-a-selective-small-molecule-inhibitor-of-glycogen-synthase-kinase-3-beta-reduces-expression-of-immune-checkpoint-molecules-pd-1-tigit-and-lag-3-and-enhances-cd8-t-cell-cy/ 2024-09-05T08:48:25+00:00 https://actuatetherapeutics.com/publications/2019-smr-gsk-3β-blockade-with-9-ing-41-in-melanoma-the-1801-phase-1-2-study/ 2024-09-05T08:50:24+00:00 https://actuatetherapeutics.com/presentations/2024-aacr-identification-of-potential-immune-biomarkers-for-gsk-3-inhibitor-elraglusib-9-ing-41-in-patients-with-relapsed-refractory-metastatic-cancer/ 2024-09-05T08:54:06+00:00 https://actuatetherapeutics.com/publications/9-ing-41-a-small-molecule-glycogen-synthase-kinase-3-inhibitor-is-active-in-neuroblastoma/ 2024-09-05T09:00:36+00:00 https://actuatetherapeutics.com/publications/2024-asco-mutational-analysis-of-cfdna-to-identify-predictive-biomarkers-in-previously-untreated-patients-with-metastatic-pancreatic-cancer-receiving-the-gsk-3-inhibitor-elraglusib-9-ing-41-in-combi/ 2024-09-05T09:04:00+00:00 https://actuatetherapeutics.com/publications/2024-asco-correlation-of-therapy-induced-neutropenia-with-survival-in-patients-with-metastatic-pancreatic-cancer-treated-with-gsk-3-inhibitor-elraglusib-9-ing-41-in-combination-with-gemcitabine-nab/ 2024-09-05T09:05:46+00:00 https://actuatetherapeutics.com/publications/microfluidic-organoid-cultures-derived-from-pancreatic-cancer-biopsies-for-personalized-testing-of-chemotherapy-and-immunotherapy/ 2024-09-05T09:09:33+00:00 https://actuatetherapeutics.com/publications/gsk-3β-in-pancreatic-cancer-spotlight-on-9-ing-41-its-therapeutic-potential-and-immune-modulatory-properties/ 2024-09-05T09:11:25+00:00 https://actuatetherapeutics.com/publications/2020-aacr-glycogen-synthase-kinase-3β-expression-in-prostate-cancer-pca-correlates-with-aggressive-pathological-features-and-its-blockade-with-9-ing-41-inhibits-viability-of-pca-cell-lines/ 2024-09-05T09:14:54+00:00 https://actuatetherapeutics.com/publications/2023-aacr-the-immunostimulatory-effect-of-9-ing-41-a-small-molecule-gsk-3-inhibitor-in-sarcomas/ 2024-09-05T09:25:19+00:00 https://actuatetherapeutics.com/publications/gsk3-beta-as-a-candidate-therapeutic-target-in-soft-tissue-sarcomas/ 2024-09-05T09:26:53+00:00 https://actuatetherapeutics.com/publications/glycogen-synthase-kinase-3β-biology-in-bone-and-soft-tissue-sarcomas/ 2024-09-05T09:28:50+00:00 https://actuatetherapeutics.com/publications/glycogen-synthase-kinase-3β-nf-κb-signaling-and-tumorigenesis-of-human-osteosarcoma/ 2024-09-05T09:30:48+00:00 https://actuatetherapeutics.com/publications/2024-asco-identification-of-immune-biomarkers-in-treatment-naive-patients-with-metastatic-pancreatic-cancer-treated-with-the-gsk-3-inhibitor-elraglusib-9-ing-41-in-combination-with-gemcitabine-nab-p/ 2024-09-06T15:52:26+00:00 https://actuatetherapeutics.com/presentations/targeting-gsk-3-a-novel-approach-to-enhance-glioblastoma-chemosensitivity/ 2024-09-06T15:55:51+00:00 https://actuatetherapeutics.com/publications/glycogen-synthase-kinase-3β-positively-regulates-protein-synthesis-and-cell-proliferation-through-the-regulation-of-translation-initiation-factor-4e-binding-protein-1/ 2024-09-06T15:58:09+00:00 https://actuatetherapeutics.com/publications/suppression-of-glycogen-synthase-kinase-3-activity-reducestumor-growth-of-prostate-cancer-invivo/ 2024-09-06T15:59:35+00:00 https://actuatetherapeutics.com/publications/phase-2-study-of-elraglusib-9-ing-41-a-glycogen-synthase-kinase-3b-inhibitor-in-combination-with-gemcitabine-plus-nab-paclitaxel-gnp-in-patients-with-previously-untreated-advanced-pancreatic-duc/ 2024-09-06T16:05:00+00:00 https://actuatetherapeutics.com/publications/clinically-relevant-gsk‑3β-inhibitor-9‑ing‑41-is-active-as-a-single-agent-and-in-combination-with-other-antitumor-therapies-in-human-renal-cancer/ 2024-09-06T16:05:54+00:00 https://actuatetherapeutics.com/publications/inhibition-of-glycogen-synthase-kinase-3-activity-leads-to-epigenetic-silencing-of-nuclear-factor-β-target-genes-and-induction-of-apoptosis-in-chronic-lymphocytic-leukemia-b-cells/ 2024-09-06T16:07:50+00:00 https://actuatetherapeutics.com/publications/phase-i-study-of-elraglusib-9-ing-41-a-glycogen-synthase-kinase-3β-inhibitor-as-monotherapy-or-combined-with-chemotherapy-in-patients-with-advanced-malignancies/ 2024-09-06T16:42:22+00:00 https://actuatetherapeutics.com/presentations/elraglusib-response-prediction-and-mechanistic-discovery-using-iterative-machine-learning/ 2024-09-06T16:47:35+00:00 https://actuatetherapeutics.com/presentations/2021-sitc-9-ing-41-a-selective-small-molecule-inhibitor-of-glycogen-synthase-kinase-3-beta-gsk-3beta-may-enhance-neuroblastoma-immunogenicity/ 2024-09-06T16:56:59+00:00 https://actuatetherapeutics.com/presentations/9-ing-41-a-small-molecule-selective-glycogen-synthase-kinase-3-beta-gsk-3β-inhibitor-progress-to-date-in-adult-patients-with-cancer/ 2024-09-06T17:34:20+00:00 https://actuatetherapeutics.com/presentations/glycogen-synthase-kinase-3β-inhibition-attenuates-the-progression-of-pulmonary-fibrosis/ 2024-09-06T17:35:08+00:00 https://actuatetherapeutics.com/publications/glycogen-synthase-kinase-3βinhibition-with-9-ing-41attenuates-the-progression-ofpulmonary-fibrosis/ 2024-09-06T17:36:16+00:00 https://actuatetherapeutics.com/publications/inhibition-of-gsk3α-β-impairs-the-progression-of-hnscc/ 2024-09-06T17:45:12+00:00 https://actuatetherapeutics.com/publications/inhibition-of-glycogen-synthase-kinase-3-blocks-mesomesenchymal-transition-and-attenuates-streptococcus-pneumoniaemediated-pleural-injury-in-mice/ 2024-09-06T17:47:06+00:00 https://actuatetherapeutics.com/publications/combination-treatment-with-the-gsk-3-inhibitor-9-ing-41-and-ccnu-cures-orthotopic-chemoresistant-glioblastoma-in-patient-derived-xenograft-models12/ 2024-09-06T17:48:49+00:00 https://actuatetherapeutics.com/publications/molecular-pathways-revisiting-glycogen-synthase-kinase-3-as-a-target-for-the-treatment-of-cancer/ 2024-09-06T17:49:39+00:00 https://actuatetherapeutics.com/publications/inhibition-of-gsk-3-induces-differentiation-and-impairedglucose-metabolism-in-renal-cancer/ 2024-09-06T17:50:46+00:00 https://actuatetherapeutics.com/publications/glycogen-synthase-kinase-3-regulates-multiple-myeloma-cell-growth-and-bortezomib-induced-cell-death/ 2024-09-06T17:53:29+00:00 https://actuatetherapeutics.com/publications/glycogen-synthase-kinase-3β-a-prognostic-marker-and-a-potential-therapeutic-target-in-human-bladder-cancer/ 2024-09-06T17:54:17+00:00 https://actuatetherapeutics.com/publications/gsk3-regulates-differentiation-and-growth-arrest-in-glioblastoma/ 2024-09-07T08:31:17+00:00 https://actuatetherapeutics.com/publications/from-a-natural-product-lead-to-the-identification-of-potent-and-selective-benzofuran-3-yl-indol-3-ylmaleimides-as-glycogen-synthase-kinase-3-inhibitors-that-suppress-proliferation-and-survival/ 2024-09-07T08:32:42+00:00 https://actuatetherapeutics.com/publications/potential-therapeutic-effect-of-glycogen-synthase-kinase-3β-inhibition-against-human-glioblastoma/ 2024-09-07T08:33:32+00:00 https://actuatetherapeutics.com/publications/glycogen-synthase-kinase-3-inhibition-induces-glioma-cell-death-through-c-myc-nuclear-factor-kb-and-glucose-regulation/ 2024-09-07T08:35:00+00:00 https://actuatetherapeutics.com/publications/aberrant-nuclear-accumulation-of-glycogen-synthase-kinase-3-in-human-pancreatic-cancer-association-with-kinase-activity-and-tumor-dedifferentiation/ 2024-09-07T08:36:14+00:00 https://actuatetherapeutics.com/publications/glycogen-synthase-kinase-3-participates-in-nuclear-factor-b-mediated-gene-transcription-and-cell-survival-in-pancreatic-cancer-cells/ 2024-09-07T08:37:51+00:00 https://actuatetherapeutics.com/publications/a-new-strategy-for-adult-t-cell-leukemia-treatment-targeting-glycogen-synthase-kinase-3β/ 2024-09-24T08:53:26+00:00 https://actuatetherapeutics.com/publications/targeted-inhibition-of-glycogen-synthase-kinase-3-using-9-ing-41-elraglusib-enhances-cd8-t-cell-reactivity-against-neuroblastoma-cells/ 2024-09-24T08:55:41+00:00 https://actuatetherapeutics.com/presentations/folfirinox-with-glycogen-synthase-kinase-3-beta-gsk-3β-inhibitor-elraglusib-and-transforming-growth-factor-β-tgfβ-inhibitor-losartan-in-untreated-metastatic-pancreatic-ductal-adeno/ 2024-09-24T15:11:40+00:00 https://actuatetherapeutics.com/publications/glycogen-synthase-kinase-3-inhibition-sensitizes-pancreatic-cancer-cells-to-chemotherapy-by-abrogating-the-topbp1-atr-mediated-dna-damage-response/ 2024-09-26T08:17:57+00:00 https://actuatetherapeutics.com/publications/phase-2-study-of-9-ing-41-a-small-molecule-selective-glycogen-synthase-kinase-3-beta-gsk-3b-inhibitor-with-gemcitabine-nab-paclitaxel-gnp-in-first-line-advanced-pancreatic-ductal-adenocarcinoma/ 2024-09-26T08:18:31+00:00 https://actuatetherapeutics.com/publications/2020-aacr-9-ing-41-a-gsk-3β-selective-small-molecule-inhibitor-in-combination-with-ruxolitinib-in-jak2617f-primary-myelofibrosis/ 2024-11-04T11:11:15+00:00 https://actuatetherapeutics.com/publications/gsk-3-a-multifaceted-player-in-acute-leukemias/ 2024-11-05T08:22:23+00:00 https://actuatetherapeutics.com/publications/repression-of-gsk3-restores-nk-cell-cytotoxicity-in-aml-patients/ 2024-11-05T08:24:54+00:00 https://actuatetherapeutics.com/publications/gsk3-is-a-regulator-of-rar-mediated-differentiation/ 2024-11-05T08:26:35+00:00 https://actuatetherapeutics.com/publications/glycogen-synthase-kinase-3b-inhibitors-suppress-leukemia-cell-growth/ 2024-11-05T12:45:29+00:00 https://actuatetherapeutics.com/publications/glycogen-synthase-kinase-3b-inhibition-induces-nuclear-factor-kb-mediated-apoptosis-in-pediatric-acute-lymphocyte-leukemia-cells/ 2024-11-05T13:03:04+00:00 https://actuatetherapeutics.com/presentations/2024-aacr-genome-wide-crispr-cas9-library-screening-identifies-aurora-kinase-a-as-a-regulator-of-elraglusib-sensitivity-in-pancreatic-cancer/ 2025-01-28T09:05:05+00:00 https://actuatetherapeutics.com/publications/glycogen-synthase-kinase-3-activity-enhances-liver-inflammation-in-mash/ 2025-01-28T09:09:57+00:00 https://actuatetherapeutics.com/publications/glycogen-synthase-kinase-3beta-inhibition-preserves-hematopoietic-stem-cell-activity-and-inhibits-leukemic-cell-growth/ 2025-01-28T09:10:33+00:00 https://actuatetherapeutics.com/publications/phase-ii-study-of-elraglusib-9-ing-41-a-gsk-3β-inhibitor-in-combination-with-gemcitabine-plus-nab-paclitaxel-in-previously-untreated-metastatic-pancreatic-cancer/ 2025-05-22T08:36:11+00:00 https://actuatetherapeutics.com/presentations/2025-aacr-elraglusib-a-glycogen-synthase-kinase-3β-gsk-3β-inhibitor-plus-chemotherapy-with-or-without-immunotherapy-for-advanced-salivary-gland-cancer/ 2025-05-22T12:40:22+00:00 https://actuatetherapeutics.com/publications/potential-therapeutic-gsk-3β-inhibitor-9-ing-41-is-active-in-combination-with-venetoclax-in-double-hit-lymphoma-dhl/ 2025-11-26T10:30:45+00:00 https://actuatetherapeutics.com/publications/apoe4-upregulates-gsk-3β-to-aggravate-alzheimer-like-pathologies-and-cognitive-impairment-in-type-2-diabetic-mice/ 2025-11-26T10:32:39+00:00 https://actuatetherapeutics.com/publications/elraglusib-a-glycogen-synthase-kinase-3β-gsk-3β-inhibitor-plus-chemotherapy-with-or-without-immunotherapy-in-patients-with-recurrent-metastatic-salivary-gland-carcinoma/ 2025-11-26T10:41:12+00:00 https://actuatetherapeutics.com/publications/perturbing-lsd1-and-wnt-rewires-transcription-to-synergistically-induce-aml-differentiation/ 2025-11-26T10:41:26+00:00 https://actuatetherapeutics.com/publications/therapeutic-targeting-of-epithelial-mesenchymal-cellular-plasticity-in-pancreatic-cancer/ 2026-03-24T12:55:44+00:00 https://actuatetherapeutics.com/publications/elraglusib-and-chemotherapy-in-metastatic-pancreatic-ductal-adenocarcinoma-a-randomized-controlled-phase-2-trial/ 2026-04-20T09:20:03+00:00 https://actuatetherapeutics.com/presentations/the-glycogen-synthase-kinase-3β-inhibitor-9-ing-41-in-combination-with-chemoimmunotherapy-provides-long-term-survival-in-the-th-mycn-mouse-model/ 2026-04-22T08:42:34+00:00 https://actuatetherapeutics.com/presentations/post-hoc-efficacy-and-biomarker-analysis-of-elraglusib-plus-gemcitabine-nab-paclitaxel-versus-chemotherapy-alone-in-metastatic-pancreatic-ductal-adenocarcinoma/ 2026-06-02T09:03:48+00:00 https://actuatetherapeutics.com/presentations/machine-learning-and-statistical-prediction-of-overall-survival-os-from-pre-dose-plasma-biomarkers-in-a-randomized-phase-2-trial-1801-part-38-of-the-gsk-3-inhibitor-elraglusib-with-gemcitabine-nab/ 2026-06-02T09:06:23+00:00 https://actuatetherapeutics.com/presentations/2026-aacr-inhibition-of-gsk3b-signaling-in-pediatric-brain-tumors/ 2026-06-02T09:08:03+00:00 https://actuatetherapeutics.com/presentations/a-phase-ii-study-of-folfirinox-ffx-combined-with-the-glycogen-synthase-kinase-3-beta-gsk-3β-inhibitor-elraglusib-elra-and-the-transforming-growth-factor-β-tgf-β-inhibitor-losart/ 2026-06-02T12:28:49+00:00